Are There Peptide Protocols for Perimenopausal Women?

Perimenopause does not begin when your periods stop. It begins years earlier, quietly, and the first thing that changes is not estrogen.

Progesterone drops first. The reason is mechanical. Each month, when your ovary releases an egg, the empty follicle transforms into a temporary gland called the corpus luteum, and that gland produces progesterone for the second half of your cycle. When ovulation becomes inconsistent, which is what happens in the early years of perimenopause, the corpus luteum does not form reliably, and progesterone output falls. Estrogen, meanwhile, keeps getting produced by your ovarian follicles, which are still there and still active, just unpredictably so.

This is the part most people get wrong about perimenopause. They assume both hormones decline together. They do not.

Research by Santoro and colleagues published in the Journal of Clinical Endocrinology and Metabolism showed that during perimenopause, estrogen does not simply fall. It becomes erratic, spiking higher than levels typical of a woman's twenties before crashing, then spiking again. The pattern is irregular and unpredictable. What breaks is not the level of either hormone in isolation. What breaks is the ratio between them.

Progesterone normally provides a counterbalance to estrogen. When that counterbalance disappears, estrogen operates essentially unopposed, and that is what drives most of what you are experiencing. The sleep disruption, the visceral fat accumulating around your midsection despite no change in diet or training, the anxiety, the mood shifts, the body composition changes that feel disconnected from anything you are doing. These are symptoms of a broken ratio, not simply a hormonal decline.

So the first question is not which peptide to add. The first question is which hormone to replace, and in what order.

Because estrogen is still being produced, sometimes in excess, the correct first step is progesterone replacement, not estrogen. Adding estrogen when your ovaries are still unpredictably producing it can amplify the erratic swings rather than stabilize them. A 2023 Phase III randomized controlled trial published in Scientific Reports looked at oral micronized progesterone in perimenopausal women and found measurable improvements in sleep quality and significant reductions in night sweats compared to placebo. Not estrogen. Progesterone alone, addressing the actual deficiency that exists at that stage.

The question of when to add estrogen has a useful clinical marker. Something called anti-Mullerian hormone, which is a protein produced by follicles in your ovaries that indicates how much ovarian reserve remains, gives your doctor a way to estimate where you are in the process. In the Penn Ovarian Aging Study, Freeman and colleagues tracked 401 women over 14 years and found that AMH levels predict the timing of menopause transition. When AMH becomes essentially undetectable and you have gone 12 consecutive months without a period, the clinical definition of menopause is met, ovarian estrogen production has stopped, and estrogen replacement becomes appropriate.

That sequencing matters before any conversation about peptides, because peptides are not a substitute for it.

There are three areas where peptides can provide meaningful support during perimenopause, and it helps to understand each one as managing a downstream consequence of the hormonal disruption rather than correcting the disruption itself.

The first is metabolic. The loss of progesterone's counterbalancing effect, combined with erratic estrogen, shifts the body toward fat storage, particularly visceral fat. GLP-1 receptor agonists and dual agonists like tirzepatide, or broader triple agonists like retatrutide, can help regulate appetite signaling and reduce what is often described as food noise, the persistent low-level drive to eat that becomes harder to override when metabolic hormones are dysregulated.

The second is sleep and anxiety. Progesterone has a direct calming effect on the nervous system through its conversion to a compound called allopregnanolone, which acts on GABA receptors, the same receptors that benzodiazepines target. When progesterone falls, that calming input disappears. Peptides like Selank, which appears to modulate anxiety through the GABAergic system and through effects on brain-derived neurotrophic factor, or DSIP, which stands for delta sleep-inducing peptide, may help restore some of what is lost in the sleep architecture and anxiety profile. The research on both is more limited than on the metabolic peptides, and the evidence base is not yet at the level of large randomized trials.

The third area is the growth hormone axis, and this is where the hormonal sequencing becomes directly relevant to whether peptides will even work.

Something called a growth hormone secretagogue, which is a compound that stimulates your pituitary gland to release more growth hormone, depends on the pituitary being responsive. Peptides like tesamorelin and CJC-1295 work through this mechanism. But a study by Shah and colleagues published in the Journal of Clinical Endocrinology and Metabolism found that pulsatile growth hormone secretion is significantly blunted in the absence of estradiol, with a p-value of 0.001. The mechanism appears to be that estrogen potentiates the pituitary's response to growth hormone releasing hormone. Without adequate estrogen, the pituitary simply does not respond as strongly to the secretagogue signal.

This is why the order of operations matters even for the peptides themselves. If estrogen levels are unstable or deficient and you add a growth hormone secretagogue, you are pushing on a system that cannot fully respond. The expected benefit, improved body composition, better recovery, enhanced IGF-1 production, is significantly reduced. The peptide is not broken. The upstream condition that enables it has not been met.

The practical framework that emerges from all of this is layered. Hormonal stability comes first. Progesterone replacement addresses the actual deficiency that defines perimenopause. Estrogen replacement follows once ovarian production has stopped. Once that foundation is in place, the metabolic peptides, the sleep and anxiety support, and the growth hormone secretagogues can each do the work they are designed to do.

Most symptom management fails in perimenopause not because the tools are wrong but because people reach for the downstream tools before stabilizing the upstream system. The peptides are real. The limitation is always the same.

---

References

1. Santoro et al., 2004, Journal of Clinical Endocrinology & Metabolism — progesterone declines before estrogen, estrogen becomes erratic during perimenopause
2. Freeman et al., 2012, Journal of Clinical Endocrinology & Metabolism — AMH predicts menopause timing (Penn Ovarian Aging Study, 401 women, 14 years)
3. Prior, 2014, Facts, Views & Vision in ObGyn — progesterone as appropriate first-line therapy for perimenopause
4. Shah et al., 2019, Journal of Clinical Endocrinology & Metabolism — pulsatile GH secretion significantly blunted without estradiol (P = 0.001), estrogen potentiates pituitary GHRH response
5. Prior et al., 2023, Scientific Reports — Phase III RCT, oral micronized progesterone improved sleep quality and reduced night sweats vs placebo

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness